We are live on ! Find out more
SAGE

Sage Therapeutics
SAGE

Delisted

SAGE was delisted on the 30th of July, 2025.

Back to rankings

284 hedge funds and large institutions have $8.18B invested in Sage Therapeutics in 2019 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 100 increasing their positions, 94 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

42% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 31

4% more funds holding

Funds holding: 272 → 284 (+12)

6% more repeat investments, than reductions

Existing positions increased: 100 | Existing positions reduced: 94

0% more funds holding in top 10

Funds holding in top 10: 7 → 7 (0)

0.74% less ownership

Funds ownership: 113.57% → 112.84% (-0.74%)

17% less call options, than puts

Call options by funds: $102M | Put options by funds: $124M

23% less capital invested

Capital invested by funds: $10.6B → $8.18B (-$2.46B)

Holders
284
Holders Change
+12
Holders Change %
+4.41%
% of All Funds
6.23%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.15%
New
44
Increased
100
Reduced
94
Closed
31
Calls
$102M
Puts
$124M
Net Calls
-$21.6M
Net Calls Change
+$36.9M

Top Buyers

1
Capital International Investors
Capital International Investors
California
+$86.4M
2
PHS
PFM Health Sciences
California
+$62.5M
3
Viking Global Investors
Viking Global Investors
Connecticut
+$44.1M
4
CII
Capital International Inc
California
+$41.7M
5
American Century Companies
American Century Companies
Missouri
+$34.4M

Top Sellers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$73.7M
2
FCM
Frontier Capital Management
Massachusetts
-$43M
3
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$42.9M
4
Bank of New York Mellon
Bank of New York Mellon
New York
-$39.9M
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$33.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
Ameriprise
26
Ameriprise
Minnesota
$63.8M -$1.64M -9,788 -2%
Wells Fargo
27
Wells Fargo
California
$61.7M +$8M +47,830 +12%
BAMCO Inc
28
BAMCO Inc
New York
$59.7M +$116K +692 +0.2%
AllianceBernstein
29
AllianceBernstein
Tennessee
$58.2M -$2.35M -14,025 -3%
CTA
30
Carillon Tower Advisers
Florida
$56.2M – – –
CC
31
Casdin Capital
New York
$56.1M – – –
PHS
32
PFM Health Sciences
California
$52.4M +$62.5M +373,828 New
FCM
33
Farallon Capital Management
California
$52.3M -$21.3M -127,200 -25%
HRCM
34
Hood River Capital Management
Florida
$51.4M +$441K +2,636 +0.7%
Goldman Sachs
35
Goldman Sachs
New York
$46.4M -$1.58M -9,448 -3%
Fiera Capital (Canada)
36
Fiera Capital (Canada)
Quebec, Canada
$41.4M -$967K -5,778 -2%
Northern Trust
37
Northern Trust
Illinois
$39.9M +$1.58M +9,468 +3%
New York State Common Retirement Fund
38
New York State Common Retirement Fund
New York
$37.6M -$853K -5,102 -2%
CII
39
Capital International Inc
California
$37.4M +$41.7M +249,273 +1,466%
Viking Global Investors
40
Viking Global Investors
Connecticut
$37M +$44.1M +263,466 New
Manulife (Manufacturers Life Insurance)
41
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$35.9M -$507K -3,030 -1%
Bank of America
42
Bank of America
North Carolina
$33.5M +$2.35M +14,050 +6%
PAMU
43
Pictet Asset Management (UK)
United Kingdom
$33.4M -$28.9M -172,737 -42%
Charles Schwab
44
Charles Schwab
California
$33.3M +$2.06M +12,285 +5%
Lord, Abbett & Co
45
Lord, Abbett & Co
New Jersey
$31.1M -$42.9M -256,617 -54%
UBS AM
46
UBS AM
Illinois
$25.7M -$6.53M -39,050 -18%
AAMU
47
Amundi Asset Management US
Massachusetts
$25M -$2.25M -13,475 -7%
MWNA
48
Marshall Wace North America
New York
$23.4M +$6.83M +40,843 +32%
TD Asset Management
49
TD Asset Management
Ontario, Canada
$21.2M -$1.92M -11,500 -7%
AG
50
Artal Group
Luxembourg
$21M – – –
1
2
3 4 5

SAGE Hedge Fund Activity: Q3 2019 in Review

284 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q3 2019, worth a combined $8.18B — down 23% from $10.6B a quarter earlier.

Buyers outnumbered sellers: 44 funds opened new SAGE positions and 31 closed out — a net gain of 13 holders — while 100 added to existing stakes and 94 trimmed.

The largest buyer was Capital International Investors, adding an estimated $86.4M. The largest seller was T. Rowe Price Associates, cutting an estimated $73.7M.

  • 284 institutional investors held Sage Therapeutics (SAGE) as of Q3 2019, up from 272 in Q2 2019.
  • Funds reported $8.18B of Sage Therapeutics stock for Q3 2019, down 23% quarter-over-quarter.
  • 44 funds opened new Sage Therapeutics positions in Q3 2019 and 31 closed out, a net change of +13 holders.
  • The largest Sage Therapeutics buyer in Q3 2019 was Capital International Investors, an estimated $86.4M added.
  • The largest Sage Therapeutics seller in Q3 2019 was T. Rowe Price Associates, an estimated $73.7M sold.

Based on aggregated 13F filings for Q3 2019.